The global genital warts (condyloma acuminatum) market is expected to reach a valuation of USD 1.87 Billion in 2023 and is projected to increase to USD 3 Billion by 2033, with a CAGR of 4.84%. The dynamics of the genital warts market are expected to change in the coming years owing to the expected launch of emerging drugs. Key players, such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others, are developing drugs for genital warts.
Moreover, successful, and well-communicated vaccination programs have increased public knowledge of vaccines and their advantages, resulting in greater vaccine uptake. In addition, increased vaccination coverage has been linked to a lower occurrence of genital warts.
Factors such as the rise in the prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections and growth in the male population are further anticipated to boost the overall growth of the genital warts treatment market within the forecast period. Furthermore, the genital warts market is fuelled by the increasing availability of therapies developed for self-target applications.
Additionally, the quadrivalent HPV vaccination has been proven to prevent genital warts and cervical cancer. The effectiveness of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination.
Moreover, the therapeutics landscape and genital warts market expects more patient-applied modalities that provide the simplicity of application, safety, and the benefit of self-administration. The rising incidence of various malignancies underlines the disparity in exposure and risk factors between genital wart patients and the general population. The paucity of effective data and alternate treatment regimens makes it challenging for doctors to deliver the appropriate treatment when initial treatments fail. Thus, all the factors mentioned above act as an obstruction to the growth of the genital warts market.
Lack of awareness about the diagnosis & treatment of such diseases and the high cost of treatment are some factors restricting growth. There is a high unmet need for targeted drugs with enhanced clinical profiles at low costs and convenient administration schedules. However, increasing Research and Development expenditure on oncologic diseases offers a promising future for the market in the foreseeable future.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 1.87 Billion |
| Anticipated Forecast Value (2033) | USD 3 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 4.84% |
The global industry for Genital Warts was valued at around USD 1 billion in the historical period while exhibiting a CAGR of 2.02%. The pandemic negatively affected the market but noteworthy growth was witnessed during the post-pandemic period.
Moreover, the increasing availability of therapies developed for self-target applications and the use of physical destruction treatment therapies such as Cryotherapy and other chemical treatments in treating Genital warts have augmented market growth. Considering these factors, FMI has projected the market to grow at a CAGR of 4.84%, while reaching a valuation of USD 3 Billion by end of the forecast period.
Emerging therapies to propel the Market Growth
The genital warts market is fuelled by the increasing availability of therapies developed for self-target applications. Additionally, the quadrivalent HPV vaccination has been proven to prevent genital warts and cervical cancer. The effectiveness of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination
Additionally, the growing focus of pharmaceutical manufacturers on the development of therapeutics that can be administered by the patient themselves and growing levels of availability for therapeutics designed for target applications/indications of HPV globally will also augment the genital warts treatment market in the forecast period.
Also, increasing research and development for therapies and treatments are to further extend suitable prospects for the growth of the genital warts treatment market in the near future.
Unawareness and complications regarding vaccines and therapies hinder the growth
The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that restrict genital warts market growth. In addition, current treatments for genital warts are mostly ablative or topical administrations of Imiquimod cream and Sinecatechins (Polyphenon E) ointment, but major issues with low patient compliance and high recurrence rates have been noted due to systemic adverse effects.
Furthermore, due to the length of time required for successful treatment and high recurrence rates, the present genital warts treatment paradigm, which includes manual excision of warts, is far from optimum. Patients with genital warts are more prone to develop HPV-related cancers, particularly anogenital malignancies, thus hampering the growth of this market.
The complications linked with the utilization of vaccines and therapeutics for the HPV virus might hamper the market’s growth which can be one of the challenging factors within the forecast period. Existing treatment procedures are often painful or invasive, and can have undesirable outcomes such as scarring or dyspigmentation that often requires repeat visits. This results in a decrease in the diagnostic rate, which in turn, is likely to restrain the genital warts therapeutics market.
Furthermore, there are no specific treatments available for genital warts. The most commonly used treatments are cauterization and freezing. On the other hand, topical skin medications that are generally prescribed for the treatment of warts are commonly prescribed for skin conditions and skin cancers as well. These aforementioned factors will hold back the market expansion.
In terms of revenue, North America dominated the genital warts market with a market share of 40% followed by Europe. the market is growing with a CAGR of 4.2% in the forecast period of 2023 to 2033 and is expected to attain a valuation of USD 1.5 Billion by 2033.
Well-established healthcare infrastructure, rising prevalence of STDs and genital warts cases, early adoption of advanced products, and presence of key players are major factors that are anticipated to drive the market in the region. Moreover, focus on research & development by leading players is expected to boost the market.
Asia Pacific region is projected to observe the fastest growth throughout the forecast period. Swift economic development, improvements in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely factors that contribute to regional growth.
Emerging economies of China, India, South Korea, and others are anticipated to observe strong growth in the coming years. The market is projected to grow with a CAGR of 4.5% in the forecast period and is expected to reach USD 900 Million by 2033.
Hospital pharmacies are expected to capture the largest share among distribution channels by 2033. Hospital pharmacies preserve the stock of products related to HPV-associated disorders like Genital Warts, mainly for outpatients and inpatients.
The segment will be driven by growing consumer awareness and increased investments in healthcare infrastructure across developing and underdeveloped economies.
The chemical treatment segment is expected to dominate the global genital warts therapeutics market, in terms of revenue by 2033. The use of Imiquimod (Aldara, Zyclara), Podophyllin and podofilox (Condylox), Trichloroacetic acid, and Sinecatechins (Veregen) are expected to fuel the market growth of genital warts during the forecast period.
Key players in the Genital Warts market are Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie, Sanofi S.A., AbbVie Inc, Perrigo Company PLC, Glenmark Pharmaceuticals. Some key developments in this market are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1.87 Billion |
| Market Value in 2033 | USD 3 Billion |
| Growth Rate | CAGR of 4.84% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia & Pacific; East Asia; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Mexico, Germany, The UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled | Verrica Pharmaceuticals; Tamir Biotechnology; Novan Inc.; Medicis Pharmaceuticals; Aresus Pharma; AbbVie Inc.; Sanofi S.A.; Perrigo Company PLC; Glenmark Pharmaceuticals |
| Customization | Available Upon Request |
FMI projects the global genital warts market to expand at a 4.84% value CAGR by 2033.
The global genital warts market is expected to garner a market value of USD 3 Billion by 2033.
FMI has projected North America to be one of the most profitable regions for the Genital Warts market.
APAC region is expected to grow fastest during the forecast period.
Genital Warts (Condyloma Acuminatum) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
